{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T03:01:19Z","timestamp":1787022079948,"version":"build-2736575974"},"reference-count":80,"publisher":"Public Library of Science (PLoS)","issue":"3","license":[{"start":{"date-parts":[[2021,3,18]],"date-time":"2021-03-18T00:00:00Z","timestamp":1616025600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:p>\n                    Successful CAR T cell therapy for the treatment of solid tumors requires exemplary CAR T cell expansion, persistence and fitness, and the ability to target tumor antigens safely. Here we address this constellation of critical attributes for successful cellular therapy by using integrated technologies that simplify development and derisk clinical translation. We have developed a CAR-CD19 T cell that secretes a CD19-anti-Her2 bridging protein. This cell therapy strategy exploits the ability of CD19-targeting CAR T cells to interact with CD19 on normal B cells to drive expansion, persistence and fitness. The secreted bridging protein potently binds to Her2-positive tumor cells, mediating CAR-CD19 T cell cytotoxicity\n                    <jats:italic>in vitro<\/jats:italic>\n                    and\n                    <jats:italic>in vivo<\/jats:italic>\n                    . Because of its short half-life, the secreted bridging protein will selectively accumulate at the site of highest antigen expression, ie. at the tumor. Bridging proteins that bind to multiple different tumor antigens have been created. Therefore, antigen-bridging CAR-CD19 T cells incorporate critical attributes for successful solid tumor cell therapy. This platform can be exploited to attack tumor antigens on any cancer.\n                  <\/jats:p>","DOI":"10.1371\/journal.pone.0247701","type":"journal-article","created":{"date-parts":[[2021,3,18]],"date-time":"2021-03-18T13:46:16Z","timestamp":1616075176000},"page":"e0247701","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":26,"title":["Anti-CD19 CAR T cells potently redirected to kill solid tumor cells"],"prefix":"10.1371","volume":"16","author":[{"given":"Christine","family":"Ambrose","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihe","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fay J.","family":"Dufort","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Sanford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alyssa","family":"Birt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin J.","family":"Hackel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Hombach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hinrich","family":"Abken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roy R.","family":"Lobb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4573-3764","authenticated-orcid":true,"given":"Paul D.","family":"Rennert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2021,3,18]]},"reference":[{"issue":"4","key":"pone.0247701.ref001","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1158\/1078-0432.CCR-18-2035","article-title":"FDA Approval Summary: Tisagenlecleucel for Treatment of Patients with Relapsed or Refractory B-cell Precursor Acute Lymphoblastic Leukemia","volume":"25","author":"MC O\u2019Leary","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"6","key":"pone.0247701.ref002","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1158\/1078-0432.CCR-18-2743","article-title":"FDA Approval Summary: Axicabtagene Ciloleucel for Relapsed or Refractory Large B-cell Lymphoma","volume":"25","author":"N Bouchkouj","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"1","key":"pone.0247701.ref003","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.biotechadv.2018.12.002","article-title":"Standardizing CAR-T therapy: Getting it scaled up","volume":"37","author":"X Dai","year":"2019","journal-title":"Biotechnol Adv"},{"issue":"11","key":"pone.0247701.ref004","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1016\/j.ymthe.2017.07.013","article-title":"Function of Novel Anti-CD19 Chimeric Antigen Receptors with Human Variable Regions Is Affected by Hinge and Transmembrane Domains","volume":"25","author":"L Alabanza","year":"2017","journal-title":"Mol Ther"},{"key":"pone.0247701.ref005","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.omto.2018.10.006","article-title":"Preclinical Development of Bivalent Chimeric Antigen Receptors Targeting Both CD19 and CD22","volume":"11","author":"H Qin","year":"2018","journal-title":"Mol Ther Oncolytics"},{"key":"pone.0247701.ref006","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s40425-017-0246-1","article-title":"A tandem CD19\/CD20 CAR lentiviral vector drives on-target and off-target antigen modulation in leukemia cell lines","volume":"5","author":"D Schneider","year":"2017","journal-title":"J Immunother Cancer"},{"issue":"8","key":"pone.0247701.ref007","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1517\/14712598.2015.1046430","article-title":"TRUCKs: the fourth generation of CARs","volume":"15","author":"M Chmielewski","year":"2015","journal-title":"Expert Opin Biol Ther"},{"issue":"9","key":"pone.0247701.ref008","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1038\/s41587-019-0192-1","article-title":"CAR-T cells secreting BiTEs circumvent antigen escape without detectable toxicity","volume":"37","author":"BD Choi","year":"2019","journal-title":"Nat Biotechnol"},{"issue":"Suppl 1","key":"pone.0247701.ref009","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1002\/hon.2595","article-title":"Managing the toxicities of CAR T-cell therapy","volume":"37","author":"SS Neelapu","year":"2019","journal-title":"Hematol Oncol"},{"issue":"6","key":"pone.0247701.ref010","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1038\/s41591-019-0421-7","article-title":"A safe and potent anti-CD19 CAR T cell therapy","volume":"25","author":"Z Ying","year":"2019","journal-title":"Nat Med"},{"key":"pone.0247701.ref011","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.omto.2018.12.009","article-title":"Two-Dimensional Regulation of CAR-T Cell Therapy with Orthogonal Switches","volume":"12","author":"MT Duong","year":"2019","journal-title":"Mol Ther Oncolytics"},{"issue":"499","key":"pone.0247701.ref012","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aau5907","article-title":"The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on\/off switch for CAR T cells","volume":"11","author":"K Mestermann","year":"2019","journal-title":"Sci Transl Med"},{"issue":"26","key":"pone.0247701.ref013","doi-asserted-by":"crossref","first-page":"3312","DOI":"10.1182\/blood-2016-02-629063","article-title":"CD19-targeted CAR T-cell therapeutics for hematologic malignancies: interpreting clinical outcomes to date","volume":"127","author":"JH Park","year":"2016","journal-title":"Blood"},{"issue":"5","key":"pone.0247701.ref014","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1172\/JCI125423","article-title":"CD19 CAR T cell product and disease attributes predict leukemia remission durability","volume":"129","author":"OC Finney","year":"2019","journal-title":"J Clin Invest"},{"key":"pone.0247701.ref015","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.2147\/TCRM.S146309","article-title":"The potential of CAR T therapy for relapsed or refractory pediatric and young adult B-cell ALL","volume":"14","author":"MH Forsberg","year":"2018","journal-title":"Ther Clin Risk Manag"},{"issue":"9967","key":"pone.0247701.ref016","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0140-6736(14)61403-3","article-title":"T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial","volume":"385","author":"DW Lee","year":"2015","journal-title":"Lancet"},{"key":"pone.0247701.ref017","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.3389\/fimmu.2018.01740","article-title":"CAR T Cells in Solid Tumors: Blueprints for Building Effective Therapies","volume":"9","author":"HM Knochelmann","year":"2018","journal-title":"Front Immunol"},{"issue":"8","key":"pone.0247701.ref018","doi-asserted-by":"crossref","first-page":"3544","DOI":"10.1021\/acs.molpharmaceut.9b00418","article-title":"Retargeting CD19 Chimeric Antigen Receptor T Cells via Engineered CD19-Fusion Proteins","volume":"16","author":"JR Klesmith","year":"2019","journal-title":"Mol Pharm"},{"key":"pone.0247701.ref019","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/1479-5876-11-23","article-title":"A CD19\/Fc fusion protein for detection of anti-CD19 chimeric antigen receptors","volume":"11","author":"SN De Oliveira","year":"2013","journal-title":"J Transl Med"},{"issue":"9","key":"pone.0247701.ref020","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1158\/1535-7163.MCT-17-1097","article-title":"Strategies to Address Chimeric Antigen Receptor Tonic Signaling","volume":"17","author":"A Ajina","year":"2018","journal-title":"Mol Cancer Ther"},{"issue":"9","key":"pone.0247701.ref021","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/0167-5699(94)90274-7","article-title":"The CD19\/CD21 signal transduction complex of B lymphocytes","volume":"15","author":"TF Tedder","year":"1994","journal-title":"Immunol Today"},{"issue":"7","key":"pone.0247701.ref022","doi-asserted-by":"crossref","first-page":"3278","DOI":"10.4049\/jimmunol.159.7.3278","article-title":"Regulation of B lymphocyte development and activation by the CD19\/CD21\/CD81\/Leu 13 complex requires the cytoplasmic domain of CD19","volume":"159","author":"S Sato","year":"1997","journal-title":"J Immunol"},{"issue":"144","key":"pone.0247701.ref023","doi-asserted-by":"crossref","DOI":"10.3791\/59275","article-title":"In Vitro Tumor Cell Rechallenge For Predictive Evaluation of Chimeric Antigen Receptor T Cell Antitumor Function","author":"D Wang","year":"2019","journal-title":"J Vis Exp"},{"issue":"1","key":"pone.0247701.ref024","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1046\/j.1365-2249.1996.d01-648.x","article-title":"Defective B7 expression on antigen-presenting cells underlying T cell activation abnormalities in systemic lupus erythematosus (SLE) patients","volume":"104","author":"FJ Garcia-Cozar","year":"1996","journal-title":"Clin Exp Immunol"},{"issue":"2","key":"pone.0247701.ref025","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/0090-8258(90)90032-G","article-title":"Comparative chemosensitivity profiles in four human ovarian carcinoma cell lines measuring ATP bioluminescence","volume":"38","author":"E Petru","year":"1990","journal-title":"Gynecol Oncol"},{"issue":"303","key":"pone.0247701.ref026","doi-asserted-by":"crossref","first-page":"303ra139","DOI":"10.1126\/scitranslmed.aac5415","article-title":"Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia","volume":"7","author":"DL Porter","year":"2015","journal-title":"Sci Transl Med"},{"issue":"5","key":"pone.0247701.ref027","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41591-018-0010-1","article-title":"Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia","volume":"24","author":"JA Fraietta","year":"2018","journal-title":"Nat Med"},{"issue":"481","key":"pone.0247701.ref028","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaw2127","article-title":"Driving CAR T cell translation forward","volume":"11","author":"L Schultz","year":"2019","journal-title":"Sci Transl Med"},{"issue":"10","key":"pone.0247701.ref029","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1007\/s13238-017-0440-4","article-title":"Phase I study of chimeric antigen receptor modified T cells in treating HER2-positive advanced biliary tract cancers and pancreatic cancers","volume":"9","author":"K Feng","year":"2018","journal-title":"Protein Cell."},{"key":"pone.0247701.ref030","first-page":"7","article-title":"Rational development and characterization of humanized anti-EGFR variant III chimeric antigen receptor T cells for glioblastoma","author":"LA Johnson","year":"2015","journal-title":"Sci Transl Med"},{"issue":"399","key":"pone.0247701.ref031","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaa0984","article-title":"A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma","volume":"9","author":"DM O\u2019Rourke","year":"2017","journal-title":"Sci Transl Med"},{"issue":"26","key":"pone.0247701.ref032","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1056\/NEJMoa1610497","article-title":"Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy","volume":"375","author":"CE Brown","year":"2016","journal-title":"N Engl J Med"},{"issue":"14","key":"pone.0247701.ref033","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1002\/pros.23214","article-title":"Phase I Trial of Anti-PSMA Designer CAR-T Cells in Prostate Cancer: Possible Role for Interacting Interleukin 2-T Cell Pharmacodynamics as a Determinant of Clinical Response","volume":"76","author":"RP Junghans","year":"2016","journal-title":"Prostate"},{"issue":"7","key":"pone.0247701.ref034","doi-asserted-by":"crossref","first-page":"2620","DOI":"10.1182\/blood-2006-11-059139","article-title":"Epstein Barr virus specific cytotoxic T lymphocytes expressing the anti-CD30zeta artificial chimeric T-cell receptor for immunotherapy of Hodgkin disease","volume":"110","author":"B Savoldo","year":"2007","journal-title":"Blood"},{"issue":"8","key":"pone.0247701.ref035","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1001\/jamaoncol.2017.0184","article-title":"HER2-Specific Chimeric Antigen Receptor-Modified Virus-Specific T Cells for Progressive Glioblastoma: A Phase 1 Dose-Escalation Trial","volume":"3","author":"N Ahmed","year":"2017","journal-title":"JAMA Oncol"},{"issue":"3","key":"pone.0247701.ref036","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/s41434-018-0007-x","article-title":"Driving cars to the clinic for solid tumors","volume":"25","author":"M Castellarin","year":"2018","journal-title":"Gene Ther"},{"issue":"495","key":"pone.0247701.ref037","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaw2293","article-title":"Supercharging adoptive T cell therapy to overcome solid tumor-induced immunosuppression","volume":"11","author":"S Mardiana","year":"2019","journal-title":"Sci Transl Med"},{"issue":"7786","key":"pone.0247701.ref038","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/s41586-019-1805-z","article-title":"c-Jun overexpression in CAR T cells induces exhaustion resistance","volume":"576","author":"RC Lynn","year":"2019","journal-title":"Nature"},{"issue":"1","key":"pone.0247701.ref039","doi-asserted-by":"crossref","first-page":"e3000591","DOI":"10.1371\/journal.pbio.3000591","article-title":"Yap suppresses T-cell function and infiltration in the tumor microenvironment","volume":"18","author":"E Stampouloglou","year":"2020","journal-title":"PLoS Biol"},{"issue":"6449","key":"pone.0247701.ref040","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1126\/science.aav8692","article-title":"Enhanced CAR-T cell activity against solid tumors by vaccine boosting through the chimeric receptor","volume":"365","author":"L Ma","year":"2019","journal-title":"Science"},{"key":"pone.0247701.ref041","article-title":"An RNA vaccine drives expansion and efficacy of claudin-CAR-T cells against solid tumors","author":"K Reinhard","year":"2020","journal-title":"Science"},{"issue":"3","key":"pone.0247701.ref042","doi-asserted-by":"crossref","first-page":"601","DOI":"10.4049\/jimmunol.1801687","article-title":"Cutting Edge: Synapse Propensity of Human Memory CD8 T Cells Confers Competitive Advantage over Naive Counterparts","volume":"203","author":"V Mayya","year":"2019","journal-title":"J Immunol"},{"key":"pone.0247701.ref043","article-title":"Tertiary lymphoid structures improve immunotherapy and survival in melanoma","author":"R Cabrita","year":"2020","journal-title":"Nature"},{"key":"pone.0247701.ref044","article-title":"B cells are associated with survival and immunotherapy response in sarcoma","author":"F Petitprez","year":"2020","journal-title":"Nature"},{"key":"pone.0247701.ref045","article-title":"B cells and tertiary lymphoid structures promote immunotherapy response","author":"BA Helmink","year":"2020","journal-title":"Nature"},{"issue":"9","key":"pone.0247701.ref046","doi-asserted-by":"crossref","first-page":"e2005046","DOI":"10.1371\/journal.pbio.2005046","article-title":"The human lymph node microenvironment unilaterally regulates T-cell activation and differentiation","volume":"16","author":"K Knoblich","year":"2018","journal-title":"PLoS Biol"},{"issue":"4","key":"pone.0247701.ref047","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1023\/A:1010927208180","article-title":"Role of adhesion molecules in activation signaling in T lymphocytes","volume":"21","author":"ML Dustin","year":"2001","journal-title":"J Clin Immunol"},{"issue":"2","key":"pone.0247701.ref048","doi-asserted-by":"crossref","first-page":"S53","DOI":"10.1016\/j.jaci.2009.07.008","article-title":"Immunologic messenger molecules: cytokines, interferons, and chemokines","volume":"125","author":"SP Commins","year":"2010","journal-title":"J Allergy Clin Immunol"},{"key":"pone.0247701.ref049","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1146\/annurev-immunol-030409-101308","article-title":"Functional anatomy of T cell activation and synapse formation","volume":"28","author":"DR Fooksman","year":"2010","journal-title":"Annu Rev Immunol"},{"key":"pone.0247701.ref050","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1146\/annurev.immunol.23.021704.115611","article-title":"The B7 family revisited","volume":"23","author":"RJ Greenwald","year":"2005","journal-title":"Annu Rev Immunol"},{"key":"pone.0247701.ref051","first-page":"166","article-title":"Effect of chronic endogenous antigen restimulation on CAR T cell persistence and memory formation","volume":"130","author":"Y Yang","year":"2017","journal-title":"Blood"},{"issue":"4","key":"pone.0247701.ref052","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.4049\/jimmunol.0901440","article-title":"Natural expression of the CD19 antigen impacts the long-term engraftment but not antitumor activity of CD19-specific engineered T cells","volume":"184","author":"EJ Cheadle","year":"2010","journal-title":"J Immunol"},{"issue":"4","key":"pone.0247701.ref053","doi-asserted-by":"crossref","first-page":"e279","DOI":"10.1097\/HS9.0000000000000279","article-title":"Chimeric Antigen Receptor T-Cell Therapy Clinical Results in Pediatric and Young Adult B-ALL","volume":"3","author":"AM DiNofia","year":"2019","journal-title":"Hemasphere"},{"issue":"6","key":"pone.0247701.ref054","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1007\/s11864-016-0406-4","article-title":"CAR T Cell Therapy in Acute Lymphoblastic Leukemia and Potential for Chronic Lymphocytic Leukemia","volume":"17","author":"N Singh","year":"2016","journal-title":"Curr Treat Options Oncol"},{"issue":"2","key":"pone.0247701.ref055","first-page":"35","article-title":"Pediatric Survivorship: Considerations Following CAR T-Cell Therapy","volume":"23","author":"C Callahan","year":"2019","journal-title":"Clin J Oncol Nurs"},{"issue":"2","key":"pone.0247701.ref056","first-page":"42","article-title":"Adult Survivorship: Considerations Following CAR T-Cell Therapy","volume":"23","author":"J Buitrago","year":"2019","journal-title":"Clin J Oncol Nurs"},{"issue":"4","key":"pone.0247701.ref057","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.jpeds.2006.10.067","article-title":"Clinical effects and safety of rituximab for treatment of refractory pediatric autoimmune diseases","volume":"150","author":"M El-Hallak","year":"2007","journal-title":"J Pediatr"},{"key":"pone.0247701.ref058","article-title":"Management of Chimeric Antigen Receptor (CAR) T-Cell Toxicities: A Review and Guideline for Emergency Providers.","author":"R Gupta","year":"2020","journal-title":"J Emerg Med"},{"issue":"Suppl 2","key":"pone.0247701.ref059","doi-asserted-by":"crossref","first-page":"S115","DOI":"10.3747\/co.27.5283","article-title":"Chimeric antigen receptor T cell therapy comes to clinical practice","volume":"27","author":"DA Wall","year":"2020","journal-title":"Curr Oncol"},{"key":"pone.0247701.ref060","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s40164-019-0151-z","article-title":"Development of molecular and pharmacological switches for chimeric antigen receptor T cells","volume":"8","author":"BX Wu","year":"2019","journal-title":"Exp Hematol Oncol"},{"issue":"5","key":"pone.0247701.ref061","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1182\/bloodadvances.2018028720","article-title":"Pharmacologic control of CAR-T cell function using dasatinib","volume":"3","author":"EW Weber","year":"2019","journal-title":"Blood Adv"},{"issue":"10","key":"pone.0247701.ref062","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1158\/2159-8290.CD-18-0442","article-title":"Tumor Antigen Escape from CAR T-cell Therapy","volume":"8","author":"RG Majzner","year":"2018","journal-title":"Cancer Discov"},{"key":"pone.0247701.ref063","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.3389\/fimmu.2019.01613","article-title":"Chimeric Antigen Receptor-Modified T Cell Therapy in Multiple Myeloma: Beyond B Cell Maturation Antigen","volume":"10","author":"M Timmers","year":"2019","journal-title":"Front Immunol"},{"issue":"1","key":"pone.0247701.ref064","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1111\/imr.12773","article-title":"CAR T cells for brain tumors: Lessons learned and road ahead","volume":"290","author":"D Akhavan","year":"2019","journal-title":"Immunol Rev"},{"key":"pone.0247701.ref065","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.3389\/fimmu.2017.01603","article-title":"Nanobodies and Nanobody-Based Human Heavy Chain Antibodies As Antitumor Therapeutics","volume":"8","author":"P Bannas","year":"2017","journal-title":"Front Immunol"},{"key":"pone.0247701.ref066","doi-asserted-by":"crossref","first-page":"977","DOI":"10.3389\/fimmu.2017.00977","article-title":"Single-Domain Antibodies As Versatile Affinity Reagents for Analytical and Diagnostic Applications","volume":"8","author":"G Gonzalez-Sapienza","year":"2017","journal-title":"Front Immunol"},{"issue":"5","key":"pone.0247701.ref067","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12051302","article-title":"Adaptor CAR Platforms-Next Generation of T Cell-Based Cancer Immunotherapy","volume":"12","author":"C Arndt","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"4","key":"pone.0247701.ref068","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/j.cell.2016.01.011","article-title":"Precision Tumor Recognition by T Cells With Combinatorial Antigen-Sensing Circuits","volume":"164","author":"KT Roybal","year":"2016","journal-title":"Cell"},{"key":"pone.0247701.ref069","doi-asserted-by":"crossref","first-page":"e105","DOI":"10.1038\/mtna.2013.32","article-title":"TanCAR: A Novel Bispecific Chimeric Antigen Receptor for Cancer Immunotherapy","volume":"2","author":"Z Grada","year":"2013","journal-title":"Mol Ther Nucleic Acids"},{"key":"pone.0247701.ref070","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.3389\/fonc.2019.01350","article-title":"CD19 and CD70 Dual-Target Chimeric Antigen Receptor T-Cell Therapy for the Treatment of Relapsed and Refractory Primary Central Nervous System Diffuse Large B-Cell Lymphoma","volume":"9","author":"S Tu","year":"2019","journal-title":"Front Oncol"},{"issue":"24","key":"pone.0247701.ref071","doi-asserted-by":"crossref","first-page":"7506","DOI":"10.1158\/1078-0432.CCR-19-1479","article-title":"Multispecific Targeting with Synthetic Ankyrin Repeat Motif Chimeric Antigen Receptors","volume":"25","author":"A Balakrishnan","year":"2019","journal-title":"Clin Cancer Res"},{"key":"pone.0247701.ref072","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.omtm.2018.12.009","article-title":"Engineering and Design of Chimeric Antigen Receptors.","volume":"12","author":"S Guedan","year":"2019","journal-title":"Mol Ther Methods Clin Dev"},{"key":"pone.0247701.ref073","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.ymeth.2018.10.026","article-title":"Bispecific T-cell engagers: Towards understanding variables influencing the in vitro potency and tumor selectivity and their modulation to enhance their efficacy and safety","volume":"154","author":"D. Ellerman","year":"2019","journal-title":"Methods"},{"issue":"8","key":"pone.0247701.ref074","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1158\/2159-8290.CD-18-0297","article-title":"CARs versus BiTEs: A Comparison between T Cell-Redirection Strategies for Cancer Treatment","volume":"8","author":"CY Slaney","year":"2018","journal-title":"Cancer Discov"},{"issue":"7","key":"pone.0247701.ref075","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1038\/s41571-020-0347-5","article-title":"T cell-engaging therapies\u2014BiTEs and beyond","volume":"17","author":"ME Goebeler","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"issue":"11","key":"pone.0247701.ref076","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1182\/blood.2019001694","article-title":"Tisagenlecleucel CAR T-cell therapy in secondary CNS lymphoma","volume":"134","author":"MJ Frigault","year":"2019","journal-title":"Blood"},{"issue":"8","key":"pone.0247701.ref077","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1038\/s41375-019-0437-5","article-title":"Anti-CD19 CAR-T as a feasible and safe treatment against central nervous system leukemia after intrathecal chemotherapy in adults with relapsed or refractory B-ALL","volume":"33","author":"X He","year":"2019","journal-title":"Leukemia"},{"issue":"1","key":"pone.0247701.ref078","doi-asserted-by":"crossref","first-page":"3549","DOI":"10.1038\/s41467-020-17175-8","article-title":"Tumor response and endogenous immune reactivity after administration of HER2 CAR T cells in a child with metastatic rhabdomyosarcoma","volume":"11","author":"M Hegde","year":"2020","journal-title":"Nat Commun."},{"issue":"10","key":"pone.0247701.ref079","doi-asserted-by":"crossref","first-page":"4285","DOI":"10.1073\/pnas.89.10.4285","article-title":"Humanization of an anti-p185HER2 antibody for human cancer therapy","volume":"89","author":"P Carter","year":"1992","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"16\u201317","key":"pone.0247701.ref080","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/S0161-5890(97)00144-2","article-title":"Construction and characterisation of a functional CD19 specific single chain Fv fragment for immunotherapy of B lineage leukaemia and lymphoma","volume":"34","author":"IC Nicholson","year":"1997","journal-title":"Mol Immunol"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0247701","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,23]],"date-time":"2023-10-23T07:27:17Z","timestamp":1698046037000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0247701"}},"subtitle":[],"editor":[{"given":"Joe W.","family":"Ramos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2021,3,18]]},"references-count":80,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2021,3,18]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0247701","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2020.03.25.007658","asserted-by":"object"}]},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,18]]}}}